



Joe Manchin III
Governor

STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
Bureau for Medical Services
Office of Pharmacy Services
350 Capitol Street - Room 251
Charleston, West Virginia 25301-3706
Phone: (304) 558-1700 - Fax: (304) 558-1542

Martha Yeager Walker
Secretary

Pharmaceutical and Therapeutics (P&T) Committee
February 25, 2009
Diamond Building
Rooms B10 & B11
Charleston, West Virginia

MINUTES

Members Present:

Steven R. Matulis, M.D.
David Avery, M.D.
James D. Bartsch, R.Ph.
Teresa Dunsworth, PharmD
Michael Grome, PA-C
Ahmed Faheem, M.D.
Rodney L. Fink, D.O.
Teresa Frazer, M.D., FAAP
Jeffrey V. Ashley, M.D.
Scott Brown, R.Ph.
Robert Stanton, PharmD

Members Not Present:

Harriet Nottingham, R. Ph.
Barbara Koster, MSN, RNC-ANP
Gene Makela, PharmD, BCPP

DHHR/BMS Staff Present:

Peggy King, R.Ph., Pharmacy Director
William Hopkins, Pharmacy Operations
Manager
Donna Schivelier

Contract Staff/GHS Staff Present:

Laureen Biczak, D.O.
Tim Clifford, M.D.
Eliza Mathias, CAPM
Shelagh Harvard

Other Contract Staff/State Staff Present:

Stephen Small, R.Ph., M.S., Rational Drug
Therapy Program
Eric Sears, R.Ph., Unisys

I. Call to Order

Dr. David Avery, M.D., Chairperson, called the meeting to order at 2:07 p.m.

II. Housekeeping

All parties seated at the table introduced themselves and gave a brief statement about their professional credentials and affiliations.

Dr. Biczak reviewed the PDL Compliance Report. Overall compliance with the PDL was 95.3% for calendar year 2008.

Dr. Biczak reviewed the Generic Utilization Report. Generic utilization continues to rise and as of January 2009, generic utilization was 69.4%. This rate is unadjusted for brands that are preferred over generics based on net cost considerations.

III. Approval of October 31, 2008 Meeting

Chairman Avery asked for approval of the minutes from the last meeting. A motion was made and seconded and the motion carried to approve the minutes as submitted.

IV. Public Comment Period

Kelli Frentzos, ProStrakan, discussed Sancuso.

Evette Brooks, Actelion Pharmaceuticals, discussed Tracleer.

Jeff Olson, Gilead Sciences, discussed Letairis.

V. Executive Session

The Committee adjourned to Executive Session.

VI. Therapeutic Class Reviews

Dr. Avery called for review of the Therapeutic Classes.

A. Muscle Relaxants

GHS recommended that the category of Muscle Relaxants, Oral be added to the PDL and that the following list be approved. A motion was made to accept the recommendations of GHS. The motion was seconded, votes were taken and the motion carried.

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS
MUSCLE RELAXANTS, ORAL	baclofen chlorzoxazone cyclobenzaprine dantrolene methocarbamol tizanidine	AMRIX (cyclobenzaprine) carisoprodol carisoprodol/ASA carisoprodol/ASA/codeine DANTRIUM (dantrolene) FEXMID (cyclobenzaprine) FLEXERIL (cyclobenzaprine) methocarbamol/ASA orphenadrine orphenadrine/ASA/caffeine PARAFON FORTE DSC (chlorzoxazone) ROBAXIN (methocarbamol) SKELAXIN (metaxalone) SOMA (carisoprodol) SOMA COMPOUND (carisoprodol /ASA) SOMA COMP w/ COD (carisoprodol/ASA/codeine) ZANAFLEX (tizanidine)

B. Pulmonary Antihypertensives

GHS recommended that the category of Pulmonary Antihypertensives-Endothelin Receptor Antagonists be added to the PDL and that the following list be approved. GHS recommended implementing a grandfathering rule for this class. A motion was made to accept the recommendations of GHS. The motion was seconded, votes were taken and the motion carried.

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS
PULMONARY ANTIHYPERTENSIVES-ENDOTHELIN RECEPTOR ANTAGONISTS	TRACLEER (bosentan)	LETAIRIS (ambrisentan)

C. Topical Analgesics

GHS recommended that Topical Analgesics be added as a new category to the PDL and that the class as listed in the draft PDL be approved. Dr. Fink moved that the recommendations

of GHS be accepted, with the exception of making Lidoderm non-preferred. During the discussion, Dr. Faheem moved to amend the motion to include the criteria that a clear diagnosis be necessary for approval of Lidoderm. However, Dr. Avery pointed out that the P & T Committee can only recommend criteria to the DUR. Dr. Faheem withdrew the motion. An amended motion was made to make Lidoderm non-preferred but to include a recommendation to the DUR Board that the criteria include an autoPA for the diagnosis of post-herpetic neuralgia. The motion was seconded, votes were taken and the motion carried. The category, as approved, is listed below.

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS
ANALGESICS, TOPICAL	capsaicin lidocaine lidocaine/prilocaine xylocaine	EMLA (lidocaine/prilocaine) FLECTOR PATCH (diclofenac) LIDAMANTLE (lidocaine) LIDAMANTLE HC (lidocaine/hydrocortisone) LIDODERM PATCH (lidocaine) LMX 4 (lidocaine) SYNERA (lidocaine/tetracaine) VOLTAREN GEL (diclofenac) ZOSTRIX (capsaicin)

VII. Single Drug Recommendations

Dr. Avery asked that GHS discuss the new drug reviews.

A. Aczone

GHS recommended that Aczone be made a non-preferred drug in the Acne Agents, Topical, Anti-infective category. A motion was made to accept the recommendation of GHS. The motion was seconded, votes were taken and the motion carried.

B. Astepro

GHS recommended that Astepro be made a non-preferred drug in the Intranasal Rhinitis Agents, Antihistamines category. A motion was made to accept the recommendation of GHS. The motion was seconded, votes were taken and the motion carried.

C. Durezol

GHS recommended that Durezol be made a non-preferred drug in the Ophthalmic, Anti-inflammatories, Other category. A motion was made to accept the recommendation of GHS. The motion was seconded, votes were taken and the motion carried.

D. Sancuso

GHS recommended that Sancuso be made a non-preferred drug in the Anti-emetic category. A motion was made to accept the recommendation of GHS. The motion was seconded, votes were taken and the motion carried.

Chairman Avery thanked Lynda Edwards for her contributions to the Committee, mentioned that her presence today is missed and voiced the Committee's wishes for her speedy recovery.

VIII. Next Meeting Date

The next meeting of the P&T Committee will be held on Wednesday, April 29, 2009 from 2:00-5:00 p.m. in the Diamond Building, Rooms B10-11.

IX. Other Business

Chairman Avery asked the Committee to turn in their forms.

X. Adjournment

A motion was made, was seconded, votes were taken and the motion carried to adjourn the meeting of the Pharmaceutical and Therapeutics Committee.

The meeting adjourned at 3:49 p.m.